Company: ARMP
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001104659-25-040273
Chunk: 0

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 0
---
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under §240.14a-12 ARMATA PHARMACEUTICALS, INC. (Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check the appropriate box): ☒ No fee required. ☐ Fee paid previously with preliminary materials. ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11. ARMATA PHARMACEUTICALS, INC. 5005 McConnell Avenue
Los Angeles, CA 90066 NOTICE OF ANNUAL MEETING OF SHAREHOLDERS
TO BE HELD ON JUNE 12, 2025 Dear Shareholder: You are cordially invited to attend the 2025 Annual Meeting of Shareholders (the “ meeting ” or the “ Annual Meeting ”) of Armata Pharmaceuticals, Inc., a Washington corporation (“ Armata ,” the “ Company ,” “ we ,” “ our ” or “ us ”). The meeting will be held at 8:30 a.m. (Pacific Time) on Thursday, June 12, 2025 at our principal executive offices at 5005 McConnell Avenue, Los Angeles, California 90066, for the following purposes: 1. To elect seven nominees for director to serve one-year terms expiring at the 2026 Annual Meeting of Shareholders and upon their successors being duly elected and qualified; 2. To approve, on an advisory, non-binding basis, the compensation of our named executive officers; 3. To ratify the Audit Committee’s selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025; and 4. To conduct any other business properly brought before the meeting or any adjournment or postponement thereof.